Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LUIS ANDRES GARZA

Allopathic & Osteopathic Physicians Dermatology

NPI
1427074517
CMS profile
1172449
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$20.71

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $20.71 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ViiV Healthcare Company $20.71 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LUIS ANDRES GARZA

NPI 1427074517 · CMS profile ID 1172449

Allopathic & Osteopathic Physicians / Dermatology

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427074517?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LUIS ANDRES GARZA, NPI 1427074517, CMS profile ID 1172449. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427074517?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LUIS ANDRES GARZA, NPI 1427074517, CMS profile ID 1172449. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427074517?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LUIS ANDRES GARZA, NPI 1427074517, CMS profile ID 1172449, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1427074517?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $20.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ViiV Healthcare Company $20.7104/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001009815 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,523.47 3
PY2023 $20.71 1
PY2025 $35,673.51 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $221,062.00 220
PY2024 Principal investigator $230,576.67 271
PY2023 Principal investigator $37,517.27 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

220 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $154.00 12/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541919
Principal investigator 1 Incyte Corporation $1,231.00 12/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541935
Principal investigator 1 Incyte Corporation $145.00 12/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541942
Principal investigator 1 Incyte Corporation $1,340.00 12/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541953
Principal investigator 1 Incyte Corporation $737.00 12/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541971
Principal investigator 1 Incyte Corporation $6,873.41 12/08/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542458
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541202
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541210
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541212
Principal investigator 1 Incyte Corporation $28.44 12/01/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541216
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541243
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541250
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541262
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541266
Principal investigator 1 Incyte Corporation $1,934.77 11/24/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542439
Principal investigator 1 Incyte Corporation $2,781.44 11/24/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542445
Principal investigator 1 Incyte Corporation $2,903.78 11/24/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542465
Principal investigator 1 Incyte Corporation $137.40 11/03/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541198
Principal investigator 1 Incyte Corporation $16.44 11/03/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541221
Principal investigator 1 Incyte Corporation $16.44 11/03/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541227
Principal investigator 1 Incyte Corporation $16.44 11/03/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541230
Principal investigator 1 Incyte Corporation $16.44 11/03/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541234
Principal investigator 1 Incyte Corporation $49.36 11/03/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541239
Principal investigator 1 Incyte Corporation $135.40 11/03/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541246
Principal investigator 1 Incyte Corporation $4.24 11/03/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541259
Principal investigator 1 Incyte Corporation $170.00 11/03/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542396
Principal investigator 1 Incyte Corporation $1,769.00 11/03/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542422
Principal investigator 1 Incyte Corporation $1,231.00 11/03/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542497
Principal investigator 1 Incyte Corporation $1,007.63 10/20/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542402
Principal investigator 1 Incyte Corporation $2,781.44 10/20/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542410
Principal investigator 1 Incyte Corporation $2,781.44 10/20/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542417
Principal investigator 1 Incyte Corporation $3,586.24 10/20/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542472
Principal investigator 1 Incyte Corporation $2,903.78 10/20/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542482
Principal investigator 1 Incyte Corporation $2,903.78 10/20/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542488
Principal investigator 1 Incyte Corporation $616.00 10/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541913
Principal investigator 1 Incyte Corporation $145.00 10/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541924
Principal investigator 1 Incyte Corporation $2,462.00 10/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541929
Principal investigator 1 Incyte Corporation $250.00 10/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541947
Principal investigator 1 Incyte Corporation $737.00 10/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541960
Principal investigator 1 Incyte Corporation $2,680.00 10/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541964
Principal investigator 1 Incyte Corporation $2,781.44 10/02/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542428
Principal investigator 1 Incyte Corporation $1,092.23 10/02/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542451
Principal investigator 1 Incyte Corporation $135.40 10/01/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541206
Principal investigator 1 Incyte Corporation $11.45 10/01/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541254
Principal investigator 1 Incyte Corporation $2,248.00 09/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541763
Principal investigator 1 Incyte Corporation $2,810.00 09/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541895
Principal investigator 1 Incyte Corporation $2,506.83 08/20/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542299
Principal investigator 1 Incyte Corporation $2,781.44 08/20/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542319
Principal investigator 1 Incyte Corporation $2,903.78 08/20/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542364
Principal investigator 1 Incyte Corporation $1,522.64 08/20/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542391
Principal investigator 1 Incyte Corporation $32.36 08/06/2025 Non-covered Recipient Entity
Johns Hopkins University
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542258
Principal investigator 1 Incyte Corporation $34.35 08/06/2025 Non-covered Recipient Entity
Johns Hopkins University
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542264
Principal investigator 1 Incyte Corporation $270.80 08/04/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541165
Principal investigator 1 Incyte Corporation $32.36 08/04/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541169
Principal investigator 1 Incyte Corporation $16.44 08/04/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541173
Principal investigator 1 Incyte Corporation $4.24 08/04/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541177
Principal investigator 1 Incyte Corporation $91.60 08/04/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541182
Principal investigator 1 Incyte Corporation $16.44 08/04/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541186
Principal investigator 1 Incyte Corporation $16.44 08/04/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541190
Principal investigator 1 Incyte Corporation $16.44 08/04/2025 Non-covered Recipient Entity
JOHN HOPKINS OUTPATIENT CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541194
Principal investigator 1 Incyte Corporation $1,917.90 08/01/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541797
Principal investigator 1 Incyte Corporation $340.00 07/28/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542270
Principal investigator 1 Incyte Corporation $170.00 07/28/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542276
Principal investigator 1 Incyte Corporation $737.00 07/28/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542286
Principal investigator 1 Incyte Corporation $2,580.00 07/28/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542293
Principal investigator 1 Incyte Corporation $59.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541773
Principal investigator 1 Incyte Corporation $103.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541786
Principal investigator 1 Incyte Corporation $70.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541804
Principal investigator 1 Incyte Corporation $360.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541809
Principal investigator 1 Incyte Corporation $154.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541815
Principal investigator 1 Incyte Corporation $145.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541821
Principal investigator 1 Incyte Corporation $145.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541826
Principal investigator 1 Incyte Corporation $592.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541833
Principal investigator 1 Incyte Corporation $737.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541839
Principal investigator 1 Incyte Corporation $1,608.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541845
Principal investigator 1 Incyte Corporation $110.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541849
Principal investigator 1 Incyte Corporation $140.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541854
Principal investigator 1 Incyte Corporation $1,340.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541860
Principal investigator 1 Incyte Corporation $737.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541867
Principal investigator 1 Incyte Corporation $2,345.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541870
Principal investigator 1 Incyte Corporation $1,231.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541876
Principal investigator 1 Incyte Corporation $1,231.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541880
Principal investigator 1 Incyte Corporation $296.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541885
Principal investigator 1 Incyte Corporation $154.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541902
Principal investigator 1 Incyte Corporation $154.00 07/18/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541907
Principal investigator 1 Incyte Corporation $5,159.00 07/16/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542306
Principal investigator 1 Incyte Corporation $4,422.00 07/16/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542343
Principal investigator 1 Incyte Corporation $7,370.00 07/16/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542349
Principal investigator 1 Incyte Corporation $5,933.00 07/16/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542357
Principal investigator 1 Incyte Corporation $10,440.00 07/16/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542370
Principal investigator 1 Incyte Corporation $3,685.00 07/16/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542383
Principal investigator 1 Incyte Corporation $1,466.40 07/09/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541769
Principal investigator 1 Incyte Corporation $2,384.00 07/09/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541779
Principal investigator 1 Incyte Corporation $2,131.00 07/09/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541792
Principal investigator 1 Incyte Corporation $737.00 07/09/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542312
Principal investigator 1 Incyte Corporation $680.00 07/09/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542325
Principal investigator 1 Incyte Corporation $5,012.00 07/09/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542331
Principal investigator 1 Incyte Corporation $3,693.00 07/09/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542337
Principal investigator 1 Incyte Corporation $4,020.00 07/09/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542377
Principal investigator 1 Incyte Corporation $1,522.64 06/25/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542189
Principal investigator 1 Incyte Corporation $2,781.44 06/25/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542193
Principal investigator 1 Incyte Corporation $38.33 06/25/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542198
Principal investigator 1 Incyte Corporation $1,522.64 06/25/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542205
Principal investigator 1 Incyte Corporation $2,781.44 06/25/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542210
Principal investigator 1 Incyte Corporation $2,903.78 06/25/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542216
Principal investigator 1 Incyte Corporation $2,903.78 06/25/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542223
Principal investigator 1 Incyte Corporation $2,903.78 06/25/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542229
Principal investigator 1 Incyte Corporation $2,903.78 06/25/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542239
Principal investigator 1 Incyte Corporation $2,903.78 06/25/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542245
Principal investigator 1 Incyte Corporation $1,522.64 06/25/2025 Non-covered Recipient Entity
Johns Hopkins University
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240542253
Principal investigator 1 Incyte Corporation $2,810.00 06/11/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541625
Principal investigator 1 Incyte Corporation $2,034.90 06/11/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541629
Principal investigator 1 Incyte Corporation $2,131.00 06/11/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541637
Principal investigator 1 Incyte Corporation $16.48 06/03/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541557
Principal investigator 1 Incyte Corporation $4.24 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541540
Principal investigator 1 Incyte Corporation $270.80 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541544
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541548
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541552
Principal investigator 1 Incyte Corporation $32.36 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541563
Principal investigator 1 Incyte Corporation $68.70 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541567
Principal investigator 1 Incyte Corporation $16.18 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541571
Principal investigator 1 Incyte Corporation $24.68 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541575
Principal investigator 1 Incyte Corporation $11.45 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541579
Principal investigator 1 Incyte Corporation $1,278.60 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541641
Principal investigator 1 Incyte Corporation $2,131.00 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541644
Principal investigator 1 Incyte Corporation $2,131.00 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541648
Principal investigator 1 Incyte Corporation $2,131.00 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541652
Principal investigator 1 Incyte Corporation $2.43 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541657
Principal investigator 1 Incyte Corporation $135.40 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541726
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541751
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541756
Principal investigator 1 Incyte Corporation $737.00 04/23/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541584
Principal investigator 1 Incyte Corporation $4,020.00 04/23/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541588
Principal investigator 1 Incyte Corporation $210.00 04/23/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541593
Principal investigator 1 Incyte Corporation $154.00 04/23/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541597
Principal investigator 1 Incyte Corporation $1,231.00 04/23/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541600
Principal investigator 1 Incyte Corporation $148.00 04/23/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541604
Principal investigator 1 Incyte Corporation $340.00 04/23/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541616
Principal investigator 1 Incyte Corporation $1,340.00 04/23/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541620
Principal investigator 1 Incyte Corporation $308.00 04/23/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541719
Principal investigator 1 Incyte Corporation $2,315.90 04/09/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541609
Principal investigator 1 Incyte Corporation $2,131.00 04/09/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541613
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541503
Principal investigator 1 Incyte Corporation $0.93 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541507
Principal investigator 1 Incyte Corporation $91.60 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541512
Principal investigator 1 Incyte Corporation $74.04 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541516
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541520
Principal investigator 1 Incyte Corporation $20.60 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541524
Principal investigator 1 Incyte Corporation $135.40 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541527
Principal investigator 1 Incyte Corporation $6.36 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541533
Principal investigator 1 Incyte Corporation $7.29 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541537
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541632
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541661
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541665
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541670
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541678
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541682
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541688
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541700
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541705
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541708
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541715
Principal investigator 1 Incyte Corporation $135.40 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541732
Principal investigator 1 Incyte Corporation $74.04 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541739
Principal investigator 1 Incyte Corporation $121.90 04/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541745
Principal investigator 1 Incyte Corporation $2,274.00 03/12/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541413
Principal investigator 1 Incyte Corporation $1,264.30 03/12/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541450
Principal investigator 1 Incyte Corporation $2,131.00 03/12/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541455
Principal investigator 1 Incyte Corporation $2,131.00 03/12/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541458
Principal investigator 1 Incyte Corporation $270.80 03/03/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541342
Principal investigator 1 Incyte Corporation $74.04 03/03/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541351
Principal investigator 1 Incyte Corporation $0.93 03/03/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541378
Principal investigator 1 Incyte Corporation $24.66 03/03/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541381
Principal investigator 1 Incyte Corporation $24.66 03/03/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541386
Principal investigator 1 Incyte Corporation $7.29 03/03/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541393
Principal investigator 1 Incyte Corporation $45.80 03/03/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541400
Principal investigator 1 Incyte Corporation $24.66 03/03/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541470
Principal investigator 1 Incyte Corporation $24.66 03/03/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541473
Principal investigator 1 Incyte Corporation $983.30 02/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541425
Principal investigator 1 Incyte Corporation $2,131.00 02/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541429
Principal investigator 1 Incyte Corporation $2,131.00 02/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541433
Principal investigator 1 Incyte Corporation $2,810.00 02/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541437
Principal investigator 1 Incyte Corporation $2,274.00 02/10/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541441
Principal investigator 1 Incyte Corporation $2,131.00 01/15/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541404
Principal investigator 1 Incyte Corporation $2,353.00 01/15/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541408
Principal investigator 1 Incyte Corporation $2,384.00 01/15/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541416
Principal investigator 1 Incyte Corporation $1,231.10 01/15/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541420
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541274
Principal investigator 1 Incyte Corporation $68.90 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541279
Principal investigator 1 Incyte Corporation $111.30 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541282
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541286
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541290
Principal investigator 1 Incyte Corporation $153.70 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541294
Principal investigator 1 Incyte Corporation $153.70 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541298
Principal investigator 1 Incyte Corporation $79.50 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541302
Principal investigator 1 Incyte Corporation $106.00 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541305
Principal investigator 1 Incyte Corporation $21.20 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541308
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541312
Principal investigator 1 Incyte Corporation $37.10 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541316
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541321
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541325
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541329
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541334
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541339
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541347
Principal investigator 1 Incyte Corporation $68.70 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541355
Principal investigator 1 Incyte Corporation $14.58 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541360
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541364
Principal investigator 1 Incyte Corporation $270.80 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541367
Principal investigator 1 Incyte Corporation $5.38 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541370
Principal investigator 1 Incyte Corporation $48.54 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541373
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541445
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541461
Principal investigator 1 Incyte Corporation $10.60 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541465
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541478
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541483
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541486
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541490
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541495
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240541499